Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vytrus BiotechFRA:V5P -1.25%66 EV-to-EBIT is 37.83 as of Aug. 16, 2026, which is 0% above its 10-year median of 37.67. GuruFocus rates FRA:V5P with a GF Score™ of 66/100 and a GF Value™ of €6.93 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 370 Biotechnology companies, Vytrus Biotech ranks worse than 74.86% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vytrus Biotech's Enterprise Value for the quarter that ended in Dec. 2025 was €77.51 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vytrus Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €3.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vytrus Biotech EV-to-EBIT Related Terms
Vytrus Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Vytrus Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:V5P vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Vytrus Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's EV-to-EBIT falls into.
Vytrus Biotech's current Enterprise Value is €120.36 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vytrus Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €3.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vytrus Biotech (FRA:V5P) has a EV-to-EBIT of 37.83 as of Aug. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vytrus Biotech and its competitors. This is near median its historical median of 37.67. Over the past decade, Vytrus Biotech's EV-to-EBIT has ranged from 16.12 to 71.82. According to the industry distribution chart, Vytrus Biotech ranks #277 out of 370 companies in the Biotechnology industry, placing it in the top 74.9%.
Is Vytrus Biotech's EV-to-EBIT too high?
Vytrus Biotech's current EV-to-EBIT of 37.83 is near median its 10-year median of 37.67. Over the past 10 years, this metric has ranged from a low of 16.12 to a high of 71.82. The Biotechnology industry median EV-to-EBIT is 16.25. Vytrus Biotech's value of 37.83 is 132.9% above this industry median. Based on the distribution chart, Vytrus Biotech ranks #277 out of 370 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vytrus Biotech has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #277 out of 370 companies for EV-to-EBIT. This places Vytrus Biotech in the lower half of its industry. The industry median EV-to-EBIT is 16.25. Vytrus Biotech's value of 37.83 is 132.9% above this benchmark. Historically, Vytrus Biotech's own EV-to-EBIT has ranged from 16.12 to 71.82 over the past decade. While the company's 10-year median is 37.67 vs. the industry median of 16.25, Vytrus Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.25, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vytrus Biotech's current EV-to-EBIT of 37.83 is 132.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vytrus Biotech and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vytrus Biotech's current EV-to-EBIT is 37.83, which is near median its own 10-year median of 37.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (FRA:V5P) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.93, compared to a current price of €15.75 — trading 127.3% above its estimated fair value. The current EV-to-EBIT is 37.83, which is near median its 10-year median of 37.67 and 132.9% above the Biotechnology industry median of 16.25. Vytrus Biotech's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vytrus Biotech (FRA:V5P), the current EV-to-EBIT is 37.83 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (FRA:V5P) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €15.75 is trading 127.3% above its estimated GF Value™ of €6.93.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for FRA:V5P:
EV-to-EBIT: 37.83 (near median its 10-year median of 37.67)
GF Value™: €6.93 vs. price of €15.75 (127.3% above fair value)
Industry Position: 132.9% above the Biotechnology median (#277 of 370)
No single metric tells the full story. See the FRA:V5P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
66GF Score
Get the complete analysis for FRA:V5P
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:V5P has been successfully added to your 
